A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults (HypoCCS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01088399|
Recruitment Status : Completed
First Posted : March 17, 2010
Results First Posted : April 21, 2014
Last Update Posted : April 21, 2014
The Hypopituitary Control and Complications Study "HypoCCS" is a prospective, open label, global, multicentre, observational study on routine clinical care of adults with growth hormone deficiency occurring either isolated or in combination with other pituitary hormone deficiencies. The objective of this observational study is to evaluate long-term safety and health outcomes for adult growth hormone deficient participants with or without somatropin replacement therapy. As an observational study, data are collected only as provided at the discretion of the attending physician. The participant enrolled meet the criteria of growth hormone deficiency in adults as per the Humatrope label in the country where their attending physician practices, and this diagnosis is at the discretion of the attending physician. The decision to receive somatropin or remain untreated is made by the participant in consultation with their attending physician.
While treatment of adult growth hormone deficient participants with somatropin has been shown to be safe and effective in clinical trials of 18 months duration, this observational study aims to provide information on health outcome and replacement therapy over longer periods of time for a larger number of participants in the context of the overall disease environment.
|Condition or disease||Intervention/treatment|
|Hypopituitarism Pituitary Insufficiency Growth Hormone Deficiency, Adult||Drug: Somatropin (rDNA origin)|
|Study Type :||Observational|
|Actual Enrollment :||10673 participants|
|Official Title:||The Global Hypopituitary Control and Complications Study|
|Study Start Date :||September 2002|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
Somatropin replacement treatment
Adult participants with growth hormone deficiency receiving somatropin replacement treatment.
Drug: Somatropin (rDNA origin)
Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
Adult participants with growth hormone deficiency receiving no somatropin replacement treatment.
- Clinically Significant Adverse Events [ Time Frame: Baseline to study completion (approximately 10 years) ]A summary of all reported serious adverse events (SAE) and other adverse events regardless of causality are provided in the Adverse Events module of this record.
- Cardiovascular Risk Factor-Change From Baseline in Body Mass Index (BMI) [ Time Frame: Baseline, interim time point (5 years), and study completion (10 years) ]Change in BMI was used as an indicator of cardiovascular risk. Body mass index (BMI) is an estimate of body fat based on body weight divided by height squared.
- Cardiovascular Risk Factor-Change From Baseline in Systolic (SBP) and Diastolic Blood Pressure (DBP) [ Time Frame: Baseline, interim time point (5 years), and study completion (10 years) ]Change in SBP and DBP were used as an indicator of cardiovascular risk.
- Cardiovascular Risk Factor-Change From Baseline in Cholesterol and Triglycerides [ Time Frame: Baseline, interim time point (5 years), and study completion (10 years) ]Change from baseline in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides were used as an indicator of cardiovascular risk and are presented.
- Cardiovascular Risk Factor-Change From Baseline in Waist Circumference [ Time Frame: Baseline, interim time point (5 years), and study completion (10 years) ]Change in waist circumference was used as an indicator of cardiovascular risk.
- Percentage of Participants Experiencing a Bone Fracture (Fracture Incidence) [ Time Frame: Baseline through 10 years ]
- Change From Baseline in the Total Z Score of the Disease-specific Module of the Questions of Life Satisfaction (QLS-H). [ Time Frame: Baseline, interim time point (5 years), and study completion (10 years) ]QLS-H is a self-administered, weighted, quality of life (QoL) questionnaire consisting of 9 items developed for participants with growth hormone deficiency. Scores were corrected for age, gender, and country differences, and expressed as Z-scores based on country-specific reference ranges. Participants indicate how important a certain dimension of QoL is to them and are then questioned as to their degree of satisfaction with that dimension. Each item is rated on a 5-point Likert scale ranging from not important (1) to extremely important (5) and from dissatisfied (1) to very satisfied (5). The weighted score for the degree of satisfaction (weighted satisfaction) with a particular dimension=(importance - 1)x(2 x satisfaction - 5). Total Z-score is obtained by adding the individual item scores of the 9 dimensions, and range from -108 (representing very low satisfaction) to +180 (representing very high satisfaction).
- Number of Participants Who Died While in the Study [ Time Frame: Study enrollment up to approximately 10 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01088399
|Study Director:||Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)||Eli Lilly and Company|